Dynavax Says FDA Accepts Heplisav BLA For Review - Quick Facts

Dynavax Technology To Present At Cowen And Co. Conference; Webcast At 8:40 AM ET

Dynavax Technologies Q4 Loss Widens

Dynavax Gets FDA Complete Response Letter On HEPLISAV - Quick Facts

Trade DVAX now with

6/26/2012 9:12 AM ET

Dynavax Technologies Corp. (DVAX: Quote) on Tuesday announced that the Food and Drug Administration has accepted for review the U.S. Biologics License Application for Heplisav, pursuing an indication for immunization against infection caused by all known subtypes of hepatitis B virus in adults 18 through 70 years of age.

Dynavax President and Chief Medical Officer, Tyler Martin, said, "The FDA has established February 24, 2013, as the PDUFA action date. We look forward to working with the FDA in moving HEPLISAV through the regulatory review process over the next few months."

The company expects to submit a European Marketing Authorization Application for Heplisav in the third quarter of 2012. Upon approval of the Heplisav BLA, Dynavax plans to submit a supplemental BLA for an indication in patients with chronic kidney disease.

Click here to receive FREE breaking news email alerts for Dynavax Technologies Corp and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

68 Articles Next>>

Editors Pick

Australia Consumer Morale Falls Sharply On Budget

Confidence among Australian consumers declined sharply in May to its lowest level since August 2012, driven largely by negative responses to the Federal Budget, a survey by Westpac and Melbourne Institute showed Wednesday. The index of consumer sentiment fell 7 percent in May to 97.6 from 104.9 in April. This is the lowest reading since August 2012.

NetApp Profit Tops Estimates; Boosts Buyback; Initiates Dividend

Data-storage products maker NetApp Inc. said Tuesday after the markets closed that its fourth quarter profit fell 4% from last year, hurt mainly by higher operating expenses even as revenue grew slightly. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast.

Analog Devices Profit Meets Estimate; Outlook Weak

Analog Devices, Inc. said that its second quarter profit rose slightly from last year, helped mainly by lower income tax expenses even as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations. However, the company forecast third quarter revenue and earnings below analysts' current consensus estimates.